LUMOSA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM LT3001(INTRAVENOUS ODATROLTIDE) PHASE 2B CLINICAL TRIAL IN ACUTE ISCHEMIC STROKE
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase…
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
Safety endpoint met, with encouraging signs of efficacy in trial with 23…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
